Trial Profile
A randomized, double-blind, multicenter study of visilizumab versus placebo in subjects with intravenous steroid-refractory ulcerative colitis previously responsive in a visilizumab study.
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Visilizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Abbott Biotherapeutics Corp; PDL BioPharma
- 09 Oct 2020 This trial is completed in Ireland, according to European Clinical Trials Database record.
- 09 Mar 2012 Actual patient number 25 added as reported by ClinicalTrials.gov.
- 25 Sep 2009 New trial record.